查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403491

2030 年癌症幹細胞治療市場預測：按癌症類型、治療類型、最終用戶和地區進行的全球分析

Cancer Stem Cells Therapy Market Forecasts to 2030 - Global Analysis By Cancer Type, Therapeutic Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球癌症幹細胞治療市場規模將達49億美元，預計2030年將達到111億美元，預測期內複合年成長率為12.2%。

癌症幹細胞治療涉及針對癌症幹細胞（CSC）的治療策略的開發和實施。 CSC 是腫瘤內的一群細胞，被認為具有自我更新和分化潛力。這些細胞參與腫瘤的發生、進展和抗治療性。癌症幹細胞療法旨在根除或抑制這些細胞的生長，從而解決癌症的根本原因並防止復發。

據世界衛生組織(WHO)稱，癌症是全球第一大死因，到2020年將導致約1,000萬人死亡。

個人化醫療的重要性日益增加

影響癌症進展的分子和遺傳因素的複雜性導致了基於個別患者特徵客製化治療方法的範式轉變。每種癌症幹細胞都具有獨特的分子特徵，在腫瘤的發展和復發中發揮關鍵作用。對個人化醫療的重視與針對特定細胞成分的目標無縫結合，從而實現更精確和有效的治療性介入。此外，根據每位患者獨特的基因組成客製化癌症幹細胞療法揭示了改善治療結果和減少副作用的潛力。

開發成本高

癌症幹細胞研究的複雜性，加上臨床試驗和藥物核准的嚴格監管要求，需要大量資金。闡明癌症幹細胞的複雜特性、進行臨床前測試並經歷嚴格的臨床試驗階段所需的廣泛研究增加了開發成本。此外，與這些治療方法的成功和商業性潛力相關的不確定性進一步增加了財務風險。製藥公司和研究機構面臨著平衡技術創新需求與將新型癌症幹細胞療法推向市場的財務負擔的挑戰。

增加對癌症研究的投資

隨著對癌症生物學認知的進步，人們已經認知到癌症幹細胞在腫瘤的發生和進展中發揮關鍵作用。這種認知導致公共和私營部門的研究經費激增，以揭示癌症幹細胞的複雜性並開發標靶治療。人們越來越注重識別創新治療方法和推動腫瘤學科學知識，這正在創造一個有利於新型癌症幹細胞治療方法出現的環境。

道德和監管問題

幹細胞研究（包括胚胎幹細胞）的複雜性引發了有關治療細胞來源和起源的倫理問題。這導致了持續的爭論，有時甚至是監管限制，阻礙了某些基於幹細胞的治療方法的開發和接受。此外，臨床試驗和治療方法核准的嚴格法律規範也加劇了研究人員和開發人員在將癌症幹細胞治療方法推向市場時所面臨的挑戰。

COVID-19 的影響：

這場危機凸顯了對創新治療方法的迫切需求，包括針對癌症幹細胞的創新療法，而研究活動、臨床試驗和醫療保健服務的中斷正在阻礙市場軌跡。由於資源被轉移到與大流行相關的工作、臨床試驗時間表的推遲以及患者招募方面的挑戰，癌症幹細胞治療的發展速度已經放緩。此外，經濟不確定性和醫療保健優先事項的變化正在影響該領域的資金籌措和投資模式。

乳癌幹細胞治療領域預計在預測期內規模最大

乳癌幹細胞治療領域由於其從根源治療乳癌的針對性方法，在預測期內佔據了最大的市場佔有率。針對這些特定細胞的治療可提供更有效和持久的治療結果，並減少癌症復發的機會。這種針對癌症幹細胞的精確性提高了治療的整體療效，並有助於增加市場採用和需求。此外，在闡明乳癌幹細胞分子機制方面的持續研究和進展正在進一步支持創新治療方法的開發、吸引投資並推動市場擴張。

預計基因治療領域在預測期內的複合年成長率最高。

由於先進的基因技術特異性針對和修改癌症幹細胞，預計基因治療領域將在預測期內出現良好的成長。基因療法允許引入治療基因或操縱現有基因來破壞對癌症幹細胞的生存和增殖至關重要的訊號途徑。此外，這種創新方法不僅提高了癌症治療的精確度，而且最大限度地減少了對正常細胞的損害並減少了副作用。

比最大的地區

由於乳癌、肺癌和大腸等癌症的發生率特別高，亞太地區在估計期間佔據了最大的市場佔有率。這種高疾病負擔正在刺激對先進醫學研究和治療的投資增加，創造有利於擴大癌症幹細胞治療的環境。此外，亞太地區醫療保健領域正在經歷快速的技術進步和創新，促進了尖端治療方法的開發，包括針對癌症幹細胞的治療方法。

複合年成長率最高的地區：

亞太地區注重研發，加上生物技術和製藥行業的快速成長，為發現特異性針對癌症幹細胞的新治療方法並提高治療效果鋪平了道路，因此，預計快速成長。因此，在對更精確和客製化治療的需求的推動下，癌症幹細胞治療方法的採用顯著增加。此外，該地區政府和監管機構正在積極支持醫療基礎設施、研究計劃和臨床試驗的進步，創造一個新療法能夠快速融入癌症治療主流的環境。我正在安排。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球癌症幹細胞治療市場：依癌症類型

  • 腦腫瘤幹細胞治療
  • 乳癌幹細胞治療
  • 大腸直腸癌幹細胞治療
  • 肺癌幹細胞治療
  • 攝護腺癌幹細胞治療
  • 其他癌症類型

第6章全球癌症幹細胞治療市場：依治療類型

  • 化療
  • 免疫療法
  • 放射治療
  • 幹細胞移植
  • 標靶治療
  • 分化治療
  • 基因治療
  • 基於奈米粒子的治療方法
  • 聯合治療
  • 其他治療類型

第7章全球癌症幹細胞治療市場：依最終用戶分類

  • 癌症研究
  • 醫院
  • 專科診所
  • 學術醫療中心
  • 專業醫護人員
    • 外科醫生
    • 放射腫瘤科醫生
    • 血液學家
  • 其他最終用戶

第8章全球癌症幹細胞治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • AbbVie Inc.
  • AdnaGen AG
  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • Cancer Stem Cells Co., Ltd
  • Gamida Cells
  • Glycosyn LLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novadip Biosciences
  • Novartis AG
  • OncoMed Pharmaceuticals
  • Pfizer Inc
  • Roche Holdings AG
  • Stemline Therapeutics, Inc.
  • Thermo Fisher Scientific, Inc
Product Code: SMRC24716

According to Stratistics MRC, the Global Cancer Stem Cells Therapy Market is accounted for $4.9 billion in 2023 and is expected to reach $11.1 billion by 2030 growing at a CAGR of 12.2% during the forecast period. The Cancer Stem Cells Therapy involves the development and implementation of therapeutic strategies specifically targeting cancer stem cells (CSCs), a subpopulation of cells within tumors believed to possess self-renewal and differentiation capabilities. These cells are implicated in tumor initiation, progression, and treatment resistance. Cancer stem cell therapy aims to eradicate or inhibit the growth of these cells, thereby addressing the root cause of cancer and preventing relapse.

According to World Health Organization (WHO), cancer was the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.

Market Dynamics:

Driver:

Growing emphasis on personalized medicine

Due to the intricate molecular and genetic factors influencing cancer advances, there is a paradigm shift towards tailoring treatments based on individual patient characteristics. Cancer stem cells, with their distinct molecular profiles, play a pivotal role in tumor development and recurrence. The emphasis on personalized medicine aligns seamlessly with the objective of targeting these specific cellular components, allowing for more precise and effective therapeutic interventions. Additionally, by customizing cancer stem cell therapies to the unique genetic makeup of each patient, the potential for improved treatment outcomes and reduced side effects becomes apparent.

Restraint:

High development costs

The intricate nature of cancer stem cell research, coupled with the stringent regulatory requirements for clinical trials and drug approvals, contributes to substantial financial investments. The extensive research needed to unravel the complexities of cancer stem cells, conduct preclinical studies, and progress through rigorous clinical trial phases amplifies development expenses. Moreover, the uncertainty associated with the success and commercial viability of these therapies adds to the financial risk. Pharmaceutical companies and research institutions face the challenge of balancing the imperative to innovate with the financial burden of bringing novel cancer stem cell therapies to market.

Opportunity:

Increasing investment in oncology research

As the understanding of cancer biology evolves, there is a growing recognition of the pivotal role played by cancer stem cells in tumor initiation and progression. This realization has prompted a surge in research funding, both from public and private sectors, dedicated to unraveling the complexities of cancer stem cells and developing targeted therapies. The heightened focus on identifying innovative treatment modalities and advancing scientific knowledge in oncology creates a conducive environment for the emergence of novel cancer stem cell therapies.

Threat:

Ethical and regulatory concerns

The intricate nature of stem cell research, including the use of embryonic stem cells, raises ethical considerations surrounding the source and derivation of cells for therapy. This has prompted ongoing debates and, at times, regulatory restrictions, creating hurdles in the development and acceptance of certain stem cell-based treatments. Additionally, stringent regulatory frameworks governing clinical trials and therapeutic approvals contribute to the challenges faced by researchers and developers in bringing cancer stem cell therapies to market.

COVID-19 Impact:

While the crisis emphasized the urgent need for innovative therapies, including those targeting cancer stem cells, disruptions in research activities, clinical trials, and healthcare services have impeded the market's trajectory. The redirection of resources toward pandemic-related efforts, delays in clinical trial timelines, and challenges in patient recruitment have slowed down the pace of cancer stem cell therapy development. Additionally, economic uncertainties and shifts in healthcare priorities have influenced funding availability and investment patterns in the sector.

The breast cancer stem cells therapy segment is expected to be the largest during the forecast period

Breast Cancer Stem Cells Therapy segment dominated the largest share of the market over the forecast period due to its targeted approach in treating breast cancer at its roots. The therapeutic focus on these specific cells allows for more effective and sustained treatment outcomes, reducing the likelihood of cancer relapse. This precision in targeting cancer stem cells enhances the overall efficacy of therapies, contributing to increased adoption and demand in the market. Additionally, ongoing research and advancements in understanding the molecular mechanisms of breast cancer stem cells further fuel the development of innovative therapies, attracting investments and driving market expansion.

The gene therapy segment is expected to have the highest CAGR during the forecast period

Gene Therapy segment is estimated to witness lucrative growth over the projection period due to the advanced genetic techniques to specifically target and modify cancer stem cells. Gene therapy enables the introduction of therapeutic genes or the manipulation of existing ones to disrupt the signaling pathways crucial for the survival and proliferation of cancer stem cells. Furthermore, this innovative approach not only enhances the precision of cancer treatment but also minimizes damage to normal cells, reducing side effects.

Region with largest share:

Asia Pacific region commanded the largest market share over the extrapolated period due to a surge in cancer incidence, with breast, lung, and colorectal cancers being particularly prevalent. This high disease burden has spurred increased investments in advanced medical research and treatment modalities, creating a conducive environment for the expansion of cancer stem cell therapies. Moreover, the Asia Pacific region has experienced rapid technological advancements and innovation in the healthcare sector, fostering the development of cutting-edge therapies, including those targeting cancer stem cells.

Region with highest CAGR:

Asia Pacific region is projected to grow at a rapid pace owing to a strong focus on research and development, coupled with a burgeoning biotechnology and pharmaceutical industry, has paved the way for the discovery of novel therapeutic approaches that specifically target cancer stem cells, enhancing treatment efficacy. As a result, there is a notable increase in the adoption of cancer stem cell therapies, driven by the demand for more precise and tailored treatment options. Additionally, governments and regulatory bodies in the region are also actively supporting advancements in healthcare infrastructure, research initiatives, and clinical trials, creating an environment conducive to the rapid integration of novel therapies into mainstream cancer care.

Key players in the market:

Some of the key players in Cancer Stem Cells Therapy market include AbbVie Inc., AdnaGen AG, Astellas Pharma Inc., Bristol Myers Squibb, Cancer Stem Cells Co., Ltd, Gamida Cells, Glycosyn LLC, Johnson & Johnson, Merck & Co., Inc., Novadip Biosciences, Novartis AG, OncoMed Pharmaceuticals, Pfizer Inc, Roche Holdings AG, Stemline Therapeutics, Inc. and Thermo Fisher Scientific, Inc.

Key Developments:

In December 2023, Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH. Significant unmet need remains in PNH, a chronic and rare blood disorder; despite anti-C5 therapy, a large proportion of patients can remain anemic and dependent on blood transfusions

In July 2023, US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease. Leqvio can now be used earlier in LDL-C treatment as an adjunct to diet and statin therapy for patients who have not had a cardiovascular event but are at an increased risk of heart disease

Cancer Types Covered:

  • Brain Cancer Stem Cells Therapy
  • Breast Cancer Stem Cells Therapy
  • Colorectal Cancer Stem Cells Therapy
  • Lung Cancer Stem Cells Therapy
  • Prostate Cancer Stem Cells Therapy
  • Other Cancer Types

Therapeutic Types Covered:

  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Stem Cell Transplantation
  • Targeted Therapy
  • Differentiation Therapy
  • Gene Therapy
  • Nanoparticle-Based Therapies
  • Combination Therapies
  • Other Therapeutic Types

End Users Covered:

  • Cancer Research Institutes
  • Hospitals
  • Specialty Clinics
  • Academic Medical Centers
  • Healthcare Professionals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Stem Cells Therapy Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Brain Cancer Stem Cells Therapy
  • 5.3 Breast Cancer Stem Cells Therapy
  • 5.4 Colorectal Cancer Stem Cells Therapy
  • 5.5 Lung Cancer Stem Cells Therapy
  • 5.6 Prostate Cancer Stem Cells Therapy
  • 5.7 Other Cancer Types

6 Global Cancer Stem Cells Therapy Market, By Therapeutic Type

  • 6.1 Introduction
  • 6.2 Chemotherapy
  • 6.3 Immunotherapy
  • 6.4 Radiation Therapy
  • 6.5 Stem Cell Transplantation
  • 6.6 Targeted Therapy
  • 6.7 Differentiation Therapy
  • 6.8 Gene Therapy
  • 6.9 Nanoparticle-Based Therapies
  • 6.10 Combination Therapies
  • 6.11 Other Therapeutic Types

7 Global Cancer Stem Cells Therapy Market, By End User

  • 7.1 Introduction
  • 7.2 Cancer Research Institutes
  • 7.3 Hospitals
  • 7.4 Specialty Clinics
  • 7.5 Academic Medical Centers
  • 7.6 Healthcare Professionals
    • 7.6.1 Surgeons
    • 7.6.2 Radiation Oncologists
    • 7.6.3 Hematologists
  • 7.7 Other End Users

8 Global Cancer Stem Cells Therapy Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AbbVie Inc.
  • 10.2 AdnaGen AG
  • 10.3 Astellas Pharma Inc.
  • 10.4 Bristol Myers Squibb
  • 10.5 Cancer Stem Cells Co., Ltd
  • 10.6 Gamida Cells
  • 10.7 Glycosyn LLC
  • 10.8 Johnson & Johnson
  • 10.9 Merck & Co., Inc.
  • 10.10 Novadip Biosciences
  • 10.11 Novartis AG
  • 10.12 OncoMed Pharmaceuticals
  • 10.13 Pfizer Inc
  • 10.14 Roche Holdings AG
  • 10.15 Stemline Therapeutics, Inc.
  • 10.16 Thermo Fisher Scientific, Inc

List of Tables

  • Table 1 Global Cancer Stem Cells Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Cancer Stem Cells Therapy Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 3 Global Cancer Stem Cells Therapy Market Outlook, By Brain Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 4 Global Cancer Stem Cells Therapy Market Outlook, By Breast Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 5 Global Cancer Stem Cells Therapy Market Outlook, By Colorectal Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 6 Global Cancer Stem Cells Therapy Market Outlook, By Lung Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 7 Global Cancer Stem Cells Therapy Market Outlook, By Prostate Cancer Stem Cells Therapy (2021-2030) ($MN)
  • Table 8 Global Cancer Stem Cells Therapy Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 9 Global Cancer Stem Cells Therapy Market Outlook, By Therapeutic Type (2021-2030) ($MN)
  • Table 10 Global Cancer Stem Cells Therapy Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 11 Global Cancer Stem Cells Therapy Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 12 Global Cancer Stem Cells Therapy Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 13 Global Cancer Stem Cells Therapy Market Outlook, By Stem Cell Transplantation (2021-2030) ($MN)
  • Table 14 Global Cancer Stem Cells Therapy Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 15 Global Cancer Stem Cells Therapy Market Outlook, By Differentiation Therapy (2021-2030) ($MN)
  • Table 16 Global Cancer Stem Cells Therapy Market Outlook, By Gene Therapy (2021-2030) ($MN)
  • Table 17 Global Cancer Stem Cells Therapy Market Outlook, By Nanoparticle-Based Therapies (2021-2030) ($MN)
  • Table 18 Global Cancer Stem Cells Therapy Market Outlook, By Combination Therapies (2021-2030) ($MN)
  • Table 19 Global Cancer Stem Cells Therapy Market Outlook, By Other Therapeutic Types (2021-2030) ($MN)
  • Table 20 Global Cancer Stem Cells Therapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Cancer Stem Cells Therapy Market Outlook, By Cancer Research Institutes (2021-2030) ($MN)
  • Table 22 Global Cancer Stem Cells Therapy Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Cancer Stem Cells Therapy Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 24 Global Cancer Stem Cells Therapy Market Outlook, By Academic Medical Centers (2021-2030) ($MN)
  • Table 25 Global Cancer Stem Cells Therapy Market Outlook, By Healthcare Professionals (2021-2030) ($MN)
  • Table 26 Global Cancer Stem Cells Therapy Market Outlook, By Surgeons (2021-2030) ($MN)
  • Table 27 Global Cancer Stem Cells Therapy Market Outlook, By Radiation Oncologists (2021-2030) ($MN)
  • Table 28 Global Cancer Stem Cells Therapy Market Outlook, By Hematologists (2021-2030) ($MN)
  • Table 29 Global Cancer Stem Cells Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.